Silymarin (Legalon) kezelés hatása idült alkoholos májbetegek antioxidáns védörendszerére és a lipid peroxidációra (kettös vak protokoll).

Translated title of the contribution: Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)

G. Müzes, G. Deák, I. Láng, K. Nékám, V. Niederland, J. Fehér

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.

Original languageHungarian
Pages (from-to)863-866
Number of pages4
JournalOrvosi Hetilap
Volume131
Issue number16
Publication statusPublished - Apr 22 1990

Fingerprint

Silymarin
Alcoholic Liver Diseases
Lipid Peroxidation
Antioxidants
Superoxide Dismutase
Therapeutics
Lymphocytes
Free Radical Scavengers
Glutathione Peroxidase
Malondialdehyde
Serum
Double-Blind Method
Erythrocytes
Placebos
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{392a1c160a24456cbd59cac15a40d85a,
title = "Silymarin (Legalon) kezel{\'e}s hat{\'a}sa id{\"u}lt alkoholos m{\'a}jbetegek antioxid{\'a}ns v{\'e}d{\"o}rendszer{\'e}re {\'e}s a lipid peroxid{\'a}ci{\'o}ra (kett{\"o}s vak protokoll).",
abstract = "A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.",
author = "G. M{\"u}zes and G. De{\'a}k and I. L{\'a}ng and K. N{\'e}k{\'a}m and V. Niederland and J. Feh{\'e}r",
year = "1990",
month = "4",
day = "22",
language = "Hungarian",
volume = "131",
pages = "863--866",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "16",

}

TY - JOUR

T1 - Silymarin (Legalon) kezelés hatása idült alkoholos májbetegek antioxidáns védörendszerére és a lipid peroxidációra (kettös vak protokoll).

AU - Müzes, G.

AU - Deák, G.

AU - Láng, I.

AU - Nékám, K.

AU - Niederland, V.

AU - Fehér, J.

PY - 1990/4/22

Y1 - 1990/4/22

N2 - A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.

AB - A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.

UR - http://www.scopus.com/inward/record.url?scp=0025712673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025712673&partnerID=8YFLogxK

M3 - Article

C2 - 2345633

AN - SCOPUS:0025712673

VL - 131

SP - 863

EP - 866

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 16

ER -